Agents and Actions

, Volume 40, Issue 3–4, pp 176–180 | Cite as

Acute anti-inflammatory activity and gastrointestinal tolerability of diclofenac and nitrofenac

  • A. Conforti
  • M. Donini
  • G. Brocco
  • P. Del Soldato
  • G. Benoni
  • L. Cuzzolin
Inflammation

Abstract

Diclofenac and its derivative nitrofenac were compared to test their anti-inflammatory efficacy and gastrointestinal toxicity in rats.

A similar good anti-inflammatory activity of the two drugs was observed in carrageenan oedema and a marked gastrointestinal toxicity was induced by diclofenac, while nitrofenac failed to produce gastric damage even with very high doses (50 and 100 mg/kg).

The lack of the gastric ulcers in rats treated with nitrofenac could be due to the absorption of the drug as an inactive inhibitor of PG synthesis and/or to the fact that probably nitric oxide is release in the intestine and plays an important protective role in maintaining the tissue integrity.

Keywords

Oxide Nitric Oxide Gastric Ulcer Protective Role Gastrointestinal Toxicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    K. D. Rainsford,The biochemical pathology of aspirin-induced gastric damage. Agents and Actions5, 326–344 (1975).PubMedGoogle Scholar
  2. [2]
    J. L. Carson and B. L. Strom,The gastrointestinal toxicity of the non-steroidal anti-inflammatory drugs, In:Side-Effects of Anti-inflammatory Drugs,Vol. 3 (Eds. K. D. Rainsford and G. P. Velo) pp. 1–8, Kluwer Academic Publishers, Dordrecht, Boston, Baltimore 1992.Google Scholar
  3. [3]
    M. W. Radomski, R. M. J. Palmer, N. G. Read and S. Moncada,Isolation and washing of human platelets with nitric oxide. Thromb. Res.50, 537–546 (1988).CrossRefPubMedGoogle Scholar
  4. [4]
    R. Maier, R. Menasse', L. Riesterer, C. Pericin and M. Ruegg.The pharmacology of diclofenac sodium. Rheumatol. Rehabil.2, 11–21 (1979).PubMedGoogle Scholar
  5. [5]
    C. J. Hawkey,Non-steroidal anti-inflammatory drugs and peptic ulcers. Facts and figures multiply, but do they add up? Br. Med. J.300, 278–284 (1990).Google Scholar
  6. [6]
    D. S. Rampton,Non-steroidal Antiinflammatory Drugs and the lower gastrointestinal tract. Seand. J. Gastroenterol.22, 1–4 (1987).Google Scholar
  7. [7]
    I. G. Otterness and M. L. Bliven,Laboratory models for testing non-steroidal anti-inflammatory drugs. InNon Steroidal Anti-inflammatory Drugs Vol. 5. (Ed. J. G. Lombardino) pp. 116–230, Wiley Interscience Publication, New York, Chichester, Brisbane, Toronto, Singapore 1985.Google Scholar
  8. [8]
    K. D. Rainsford and M. W. Whitehouse,Concerning the merits of copper aspirin as a potential anti-inflammatory drug. J. Pharm. Pharmacol.28, 83–86 (1976).PubMedGoogle Scholar
  9. [9]
    K. D. Rainsford and M. W. Whitehouse,Anti-inflammatory/anti-pyretic salicylic acid esters with low gastric ulcerogenic activity. Agents and Actions10, 451–456 (1980).PubMedGoogle Scholar
  10. [10]
    M. W. Radomski, R. M. J. Palmer and S. Moncada,The antiaggregating properties of vascular endothelium: Interactions between prostacyclin and nitric-oxide. Br. J. Pharmacol.92, 639–649 (1987).PubMedGoogle Scholar
  11. [11]
    T. B. McCall, N. K. Boughton-Smith, R. M. J. Palmer, B. J. Whittle and S. Moncada,Synthesis of nitrioxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem. J.261, 293–296 (1989).PubMedGoogle Scholar
  12. [12]
    S. Moncada, R. M. J. Palmer and E. A. Higgs,Nitric oxide: Physiology, pathophysiology and pharmacology, Pharmacol. Rev.43, 109–142 (1991).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1993

Authors and Affiliations

  • A. Conforti
    • 3
  • M. Donini
    • 3
  • G. Brocco
    • 1
  • P. Del Soldato
    • 2
  • G. Benoni
    • 3
  • L. Cuzzolin
    • 3
  1. 1.Institute of Chemistry and Clinical MicroscopyUniversity of VeronaVeronaItaly
  2. 2.Metgrove Ltd.UK
  3. 3.Institute of PharmacologyUniversity of VeronaVeronaItaly

Personalised recommendations